p21 Antikörper

Produktnummer ABIN105216

Produktdetails anti-p21 Antikörper

Target: p21 (CDKN1A) (Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser p21 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Produktmerkmale: Concentration Definition: by UV absorbance at 280 nm

Immunogen: This protein A purified monoclonal antibody was produced by repeated immunizations with recombinant human p21 fusion protein.
Immunogentype:Recombinant

Klon: WA-1

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: This antibody is suitable for immunohistochemistry, ELISA and immunoblotting. The antibody detects a 21 kDa band corresponding to the p21 protein.  MCF7 cells or UV treated fibroblasts are suggested as a positive control for immunoblotting and immunohistochemistry.   Methanol/acetone fixed tissue is reactive for immunohistochemistry. The antibody also reacts with breast carcinoma on frozen sections (methanol/acetone fixation) and on paraffin sections (formalin fixation and microwave treatment prior to staining).  In ELISA this monoclonal antibody is useful either as a capture antibody (attached to the solid phase) or for detection of p21 protein.  This antibody immunoprecipitates monomeric p21WAF1 and not p21 complexes with other proteins. High level expression of p21WAF1 requires induction of wild-type p53 expression (e.g. via exposure to DNA damaging agents).

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1.0 mg/mL

Buffer: 0.02 M Potassium Phosphate, 0.5 M Sodium Chloride, pH 7.2

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Referenzen für anti-p21 Antikörper (ABIN105216)

Supiot, Hill, Bristow: "Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53." in: Molecular cancer therapeutics, Vol. 7, Issue 4, pp. 993-9, (2008) (PubMed).

Joshi, Chen, Kalemkerian, Adil, Kraut, Sarkar: "Inhibition of tumor cell growth by p21WAF1 adenoviral gene transfer in lung cancer." in: Cancer gene therapy, Vol. 5, Issue 3, pp. 183-91, (1998) (PubMed).

Kagawa, Fujiwara, Hizuta, Yasuda, Zhang, Roth, Tanaka: "p53 expression overcomes p21WAF1/CIP1-mediated G1 arrest and induces apoptosis in human cancer cells." in: Oncogene, Vol. 15, Issue 16, pp. 1903-9, (1997) (PubMed).

Yang, Perkins, Ohno, Nabel, Nabel: "The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo." in: Nature medicine, Vol. 1, Issue 10, pp. 1052-6, (1996) (PubMed).

Waldman, Kinzler, Vogelstein: "p21 is necessary for the p53-mediated G1 arrest in human cancer cells." in: Cancer research, Vol. 55, Issue 22, pp. 5187-90, (1995) (PubMed).

Yeh, Shatkin: "A cis-acting element in Rous sarcoma virus long terminal repeat required for promoter repression by HeLa nuclear protein p21." in: The Journal of biological chemistry, Vol. 270, Issue 26, pp. 15815-20, (1995) (PubMed).

Details zu p21

Target: p21 (CDKN1A) (Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A))

Andere Bezeichnung: p21 WAF1 (CDKN1A Produkte)

Synonyme: CCND1 antikoerper, CDKN1A antikoerper, CAP20 antikoerper, CDKN1 antikoerper, CIP1 antikoerper, MDA-6 antikoerper, P21 antikoerper, SDI1 antikoerper, WAF1 antikoerper, p21CIP1 antikoerper, CDKI antikoerper, Cdkn1 antikoerper, Waf1 antikoerper, mda6 antikoerper, p21Cip1 antikoerper, p21WAF antikoerper, Cip1 antikoerper, UV96 antikoerper, p21 antikoerper, cip1 antikoerper, p16Xic2 antikoerper, sdi1 antikoerper, waf1 antikoerper, cap20 antikoerper, cdkn1 antikoerper, mda-6 antikoerper, p21cip1 antikoerper, si:ch1073-48m5.2 antikoerper, KRAS2 antikoerper, p21ras antikoerper, cyclin D1 antikoerper, cyclin dependent kinase inhibitor 1A antikoerper, cyclin-dependent kinase inhibitor 1A (P21) antikoerper, cyclin-dependent kinase inhibitor 1A antikoerper, cyclin-dependent kinase inhibitor 1A L homeolog antikoerper, cyclin-dependent kinase inhibitor 1 antikoerper, KRAS proto-oncogene, GTPase antikoerper, CCND1 antikoerper, CDKN1A antikoerper, Cdkn1a antikoerper, cdkn1a.L antikoerper, cki1 antikoerper, cdkn1a antikoerper, KRAS antikoerper

Hintergrund: P21WAF1 is a tumor suppressor gene product critical to maintain proper regulatory control of cell division.  p21WAF1 inhibits cyclin/cyclin-dependent kinase (cdk) complexes, causing cell cycle arrest by blocking cell division at the S phase. Various mutations of tumor suppressor genes have been associated with different types of cancers.  In these cases, somatic gene therapy with wild-type versions of tumor suppressor genes have been contemplated as anti-cancer therapeutic approaches.  p21WAF1 contains p53-binding sites in its promoter and expression of p21WAF1 is induced in WI38 fibroblasts with PMA. The induction of and
Synonyms: Cyclin-dependent kinase inhibitor 1A (p21, Cip1) antibody, DNA Synthesis Inhibitor antibody, MDA 6 antibody, MDA6 antibody, Melanoma Differentiation Associated Protein 6 antibody

Gen-ID: 1026

NCBI Accession: NP_510867

UniProt: P38936

Pathways: p53 Signalweg, PI3K-Akt Signalweg, Zellzyklus, AMPK Signaling, Fc-epsilon Rezeptor Signalübertragung, EGFR Signaling Pathway, Neurotrophin Signalübertragung, Mitotic G1-G1/S Phases, DNA Replication, Hepatitis C, Synthesis of DNA, Autophagie